According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
DRNA has been the topic of several other reports. Cowen and Company reissued a buy rating on shares of Dicerna Pharmaceuticals in a research report on Friday, August 5th. Stifel Nicolaus reissued a buy rating and set a $13.00 price target on shares of Dicerna Pharmaceuticals in a research report on Wednesday, September 28th. Chardan Capital dropped their price target on Dicerna Pharmaceuticals from $4.00 to $3.50 and set a neutral rating on the stock in a research report on Monday, August 15th. Finally, Leerink Swann reissued a buy rating on shares of Dicerna Pharmaceuticals in a research report on Thursday, June 30th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Dicerna Pharmaceuticals currently has an average rating of Buy and a consensus target price of $12.25.
Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at 5.09 on Wednesday. Dicerna Pharmaceuticals has a 52-week low of $2.69 and a 52-week high of $15.93. The stock’s market capitalization is $105.63 million. The company has a 50 day moving average of $3.92 and a 200 day moving average of $3.90.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.09. Analysts predict that Dicerna Pharmaceuticals will post ($3.17) EPS for the current fiscal year.
A number of large investors have recently modified their holdings of DRNA. Dimensional Fund Advisors LP raised its stake in shares of Dicerna Pharmaceuticals by 44.9% in the second quarter. Dimensional Fund Advisors LP now owns 34,273 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 10,616 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Dicerna Pharmaceuticals during the first quarter valued at $160,000. A.R.T. Advisors LLC bought a new stake in shares of Dicerna Pharmaceuticals during the second quarter valued at $170,000. Paloma Partners Management Co bought a new stake in shares of Dicerna Pharmaceuticals during the second quarter valued at $183,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Dicerna Pharmaceuticals during the first quarter valued at $343,000. 62.38% of the stock is currently owned by hedge funds and other institutional investors.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.